Pricing Log in Create free account

Curanex Pharmaceuticals Inc (CURX) vs GT Biopharma, Inc. (GTBP)

Curanex Pharmaceuticals Inc and GT Biopharma, Inc. are both Biotechnology companies. Curanex Pharmaceuticals Inc and GT Biopharma, Inc. are of similar size ($9.4M and $9.1M). Curanex Pharmaceuticals Inc has negative trailing earnings, so its P/E is not meaningful; GT Biopharma, Inc. trades at 0.8×. Across the 9 metrics below, GT Biopharma, Inc. leads on 6 and Curanex Pharmaceuticals Inc on 3.

Valuation

Metric CURX GTBP Biotechnology median
P/E n/m 0.76 10.60
P/S n/m 114.39 9.40
P/B 1.84 1.92 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 475.21 9.02
Earnings yield (125.60%) 130.83% (32.88%)
Free cash flow yield (137.14%) (207.77%) (23.13%)

Profitability

Metric CURX GTBP Biotechnology median
Gross margin — 41.67% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (411.10%) 102.03% (51.96%)
Return on assets (357.22%) (176.27%) (46.06%)
Return on invested capital (356.67%) 0.00% 0.00%

Growth

Metric CURX GTBP Biotechnology median
Revenue growth (TTM) — (76.19%) 6.76%
EPS growth (last fiscal year) (523.51%) 3.75% 29.88%
Revenue growth, 5-year CAGR — 19.67% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CURX GTBP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 45.95 2.61 4.97
Net debt to EBITDA 1.20 0.56 1.01

Dividend

Metric CURX GTBP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CURX GTBP Biotechnology median
Market cap 9.07m 9.36m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack